Cure My Disease

Don't miss your cure!

 Log in / Sign up

Biomarker-Guided breast cancer trial aims to personalize therapy

NCT ID NCT07340541

Recruiting now Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. The goal is to see if biomarker-driven therapy improves outcomes, with each patient acting as their own control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor negative breast cancer estrogen-receptor positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER HORMONE RECEPTOR NEGATIVE BREAST CARCINOMA METASTATIC BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599-7305, United States

  • Mayo Clinic

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

  • Yale Cancer Center Clinical Trials Office

    RECRUITING

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.